Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma

Fig. 2

Western blot validation of differentially expressed proteins in patient pools of astrocytomas and oligodendrogliomas. The same pool of patient sample used for quantitative proteomics was used for validation by immunodetection. The assay was normalized to actin

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us